Orlistat Pellets 50% – Ready to Fill Into Capsules (Dose: 60 mg, 120 mg)
Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats. Orlistat can also help to reduce risk factors, such as high blood pressure, high cholesterol and high blood sugar which, if not treated, could lead to other diseases such as hypertension and diabetes.
- MKPPL has developed Orlistat pellets equivalent to innovator product using aqueous technology.
- Multimedia Dissolution Profile is compared with Marketed Product and similarity results were within limits in all media.
- We do offer development services in case of a requirement for different formulation/dosage/strength
- Offer complete technical package for registrations in all regulated/semi regulated markets
- MKPPL offers a patent non-infringing product.
Additional information
| Percentage | 50% |
|---|---|
| Mesh Size | 14#20, 18#30 |
| Release Type | Immediate Release |
| Quality Standard | USP43, In-House |
| Documentation Available: | DMF in CTD Format |
| Forms of PFI | Pellets/Extrudes (for capsules) |
| Target Formulations | Capsules |
Description
The drug acts systemically & prevents breakdown of complex fats in to simple one by tagging to Enzyme Lipase. Since it is a systemically acting drug, in vitro dissolution profile plays a crucial role in governing the pharmacological activities.
The formula employed is non- infringing but has a time dissolution profile of the innovators [Xenical® from Roche]. This assures an optimal pharmacological index.
